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Abstract Background:A key challenge to dose selection in early central nervous system
(CNS) clinical drug development is that patient tolerability profiles often
differ from those of healthy volunteers (HVs), yet HVs are the modal popu-
lation for determining doses to be investigated in phase II trials. Without
clear tolerability data from the target patient population, first efficacy trials
may include doses that are either too high or too low, creating undue risk for
study participants and the development program overall. Bridging trials ad-
dress this challenge by carefully investigating safety and tolerability in the
target population prior to full-scale proof-of-concept trials.
Objective: Org 26576 is an alpha-amino-3-hydroxy-5-methylisoxazole-
4-propionic acid (AMPA) receptor positive allosteric modulator that acts by
modulating ionotropic AMPA-type glutamate receptors to enhance gluta-
matergic neurotransmission. In preparation for phase II efficacy trials in
major depressive disorder (MDD), two separate phase I trials were conducted
to evaluate safety, tolerability, and pharmacokinetics in HVs and in the target
patient population.
Methods: Both trials were randomized and placebo controlled, and in-
cluded multiple rising-dose cohorts (HV range 100–400mg bid; MDD range
100–600mg bid). HVs (n= 36) and patients with MDD (n = 54) were dosed
under similarly controlled conditions in an inpatient facility, HVs for up to
14 days and MDD patients for up to 28 days. Safety, tolerability, and
pharmacokinetics were assessed frequently.
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Results: Despite comparable pharmacokinetic profiles, the maximum tolerated
dose (MTD) in depressed patients was 450mg bid, twice theMTD established in
HVs. No clinically relevant safety issues associated with Org 26576 were noted.
Conclusion: This article presents safety, tolerability, and pharmacokinetic
data from two different populations examined under similar dosing condi-
tions. The important implications of such bridging work in phase II dose
selection are discussed, as are study design and data interpretation challenges.
Introduction
One of the critical challenges in early-stage
clinical drug development is the selection of ap-
propriate doses for initial efficacy trials. The lack
of validated biomarkers in most central nervous
system (CNS) indications leads to phase II dose
and regimen selection that is often based on a best
guess for efficacy and on safety/tolerability es-
tablished in preclinical and early phase I work.
Although human tolerability is most often de-
termined via early studies in healthy volunteers
(HVs), there is good evidence that tolerability
profiles in healthy subjects do not necessarily pre-
dict tolerability in target patient populations,
particularly in CNS disorders.[1] Bridging studies,
sometimes known as phase Ib studies, offer a
unique opportunity to examine tolerability in target
populations in support of dose selection for phase
II efficacy trials. Establishing the patient max-
imum tolerated dose (MTD) as early as possible
not only reduces the risk that patients in proof-
of-concept trials will be over- or under-exposed
to study medication, but also can result in accel-
eration of the drug development timeline.[2] These
trials also provide the opportunity to assess pre-
liminary dose and/or pharmacokinetic relation-
ships with pharmacodynamic measures, including
electrophysiologic or neurochemical biomarkers,
as well as cognitive or behavioral endpoints.[3,4]
Much of the published bridging work to date
has been conducted in Alzheimer’s disease and
schizophrenia, where small numbers of otherwise
healthy patients are exposed to escalating doses
of the study drug under controlled conditions.[5]
Although there is variability between trials, the
MTD is generally defined as the dose one level (or
‘step’) below the dose that causes an unacceptable
number of discontinuations or dose-limiting ad-
verse events (AEs).[6] Doses included in these
bridging trials are often selected on the basis of
HV data, with an expanded range to allow for the
possibility that patient and HV tolerability may
differ. Indeed, bridging trials have often led to
conclusions that were disparate from those that
might have been drawn on the basis of HV data
alone.[7-15] Despite relatively comparable pharma-
cokinetic profiles in most cases, the resulting
MTD in these trials was determined to be higher
than – and in some cases a multiple of – the MTD
in HVs. Importantly, there is no evidence from
these trials that safety profiles (i.e. findings on
objective safety measures) differ between HVs
and patients; the differences appear to be limited
to tolerability (i.e. AEs).
The reason for this population-dependent tol-
erability phenomenon is largely unknown, but it
has been suggested that it is due to alteration of
receptor activity by prior treatments or by the
disease itself.[16] Still, one must exercise caution
when drawing generalized conclusions. Although
the majority of studies indicate that patients are
able to tolerate higher doses than HVs, there are
examples where there is no difference or even the
opposite is true.[2,17] Furthermore, conflicting
outcomes within the same drug class (e.g. ace-
tylcholinesterase inhibitors)[12,17] suggest that spe-
cific molecule differences may play a contributory
role. Such divergent findings underscore the im-
portance of carefully evaluating tolerability in the
target population prior to embarking on phase II
efficacy trials of any new investigational drug.
While the cumulative MTD literature in schizo-
phrenia and Alzheimer’s disease can lend some
guidance to drug developers in the CNS arena,
published data are comparatively sparse for other
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indications, including major depressive disorder
(MDD).
The current paper summarizes the bridging data
for Org 26576 (chemical name: [9aS]-8,9,9a,10-
tetrahydro-5H,7H-pyrido[3,2-f]pyrrolo[2,1-c][1,4]
oxazepin-5-one; see figure 1). Org 26576 belongs
to a novel class of compounds referred to as alpha-
amino-3-hydroxy-5-methylisoxazole-4-propionic
acid receptor positive allosteric modulators (AMPA
PAMs), which act by modulating ionotropic
AMPA-type glutamate receptors to enhance glu-
tamatergic neurotransmission.[18,19] Dysregulation
of the glutamatergic system has been implicated
in the pathology of psychiatric diseases such as
schizophrenia[20,21] and mood disorders.[22-24]
AMPA receptors mediate fast excitatory neuro-
transmission in the brain, and their activation has
been reported to exert a variety of cellular effects,
including enhancement of neurotrophic factor
activity (particularly brain-derived neurotrophic
factor [BDNF]),[25] synaptic plasticity,[26] and neu-
rogenesis.[27] It has been suggested that modu-
lation of these cellular activities may, in part, play
a role in the mode of action of current antide-
pressant agents.[28,29] If so, AMPA PAMs repre-
sent a promising novel approach in MDD.
The two trials presented here were undertaken
by employing very similar designs and dosing ap-
proaches in order to characterize the tolerability,
safety, and pharmacokinetic profiles of Org 26576
both in HVs and in patients diagnosed withMDD.
The overarching program objective of these trials
was to facilitate dose selection for the first proof-
of-concept trials with Org 26576 in MDD. HV
and patient safety/tolerability and pharmaco-
kinetic data that contributed to dosing decisions
are presented here. Secondary, exploratory phar-
macodynamic endpoints from the patient trial
are presented elsewhere.[30]
Methods
Study Design and Subjects
The studies described herein were conducted
in accordance with the principles of Good Clin-
ical Practice and were approved by each center’s
institutional review board and the appropriate
regulatory agency prior to commencement of study
activities. All study participants signed an informed
consent form before any screening evaluations were
performed. Study objectives of both trials were
to assess the safety and tolerability, MTD, phar-
macokinetics, and pharmacodynamics of Org
26576.
Study 1: A Combined Single- and Multiple-Oral-
Dose Tolerability and Pharmacokinetic Study of
Org 26576 in Healthy Male Subjects (Organon
Protocol 21301)
This study was conducted at Guy’s Drug Re-
search Unit, Quintiles Ltd, London, UK, between
June and November 2005. This was a randomized,
double-blind, crossover, placebo-controlled, single-
rising-dose study (part I), and a randomized,
double-blind, parallel-group, placebo-controlled,
multiple-rising-dose study (part II) in healthy
male volunteers aged 18 to 45 years. In the single-
dose part of the study (part I), two groups of nine
subjects each participated in three successive pe-
riods during which they received a single dose of
Org 26576 (range 5–250mg) on two separate oc-
casions and a single dose of placebo on one oc-
casion. The washout period between successive
dosing occasions was at least 7 days.
The multiple-dose part of the study (part II)
included two sequential nine-subject groups,
where six in each group received Org 26576 and
three received placebo. In part II, group 3 sub-
jects received either a single dose of Org 26576
(100mg) or placebo on 3 of 9 days and twice-
daily (bid) doses at 12-hour intervals on days 3–8.
In this group, the effect of food (a high-fat break-
fast) on the pharmacokinetics of Org 26576 was
investigated on day 5; four subjects received the
morning dose after a standardized high-fat break-
fast, and five subjects received the morning dose
after an overnight fast. Subjects received the op-






Fig. 1. Chemical structure of Org 26576.
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was permitted until 4 hours post-dose. In part II,
group 4 utilized a multiple-rising-dose design to
determine the MTD. Subjects received either
Org 26576 or placebo at 12-hour intervals; start-
ing doses were based on tolerability results from
previous groups and were carefully escalated in
interim steps of 1.25–1.5 times the previous dose
as follows: 100mg bid on days 1 and 2, 150mg
bid on days 3–5, 225mg bid on days 6–8, 325mg
bid on days 9–11, 400mg bid on days 12 and 13,
and a single 400mg dose on day 14.
Study 2: Multiple-Oral-Dose Tolerability and
Pharmacokinetics of Org 26576 in Patients
Diagnosed with Major Depressive Disorder
(Organon Protocol 174001)
This study was conducted at California Clinical
Trials in Glendale, CA, USA, between September
2007 and December 2008 (clinicaltrials.gov iden-
tifier: NCT00610649). Part I was a randomized,
double-blind, placebo-controlled, multiple-rising-
dose evaluation in 24 patients. Four sequential
cohorts of six patients each received either Org
26576 or placebo in a 2 : 1 ratio (cohort A dose
titration: 100mg bid on days 1–3, 200mg bid on
days 4–6, 300mg bid on days 7–9, 450mg bid on
days 10–12, 600mg bid on days 13–16). Within
part I, cohorts A, B, and C started at progressively
higher doses (100mg, 200mg, or 300mg), all ris-
ing to 600mg bid, in order to explore the optimal
titration schedule; cohort D evaluated cerebro-
spinal fluid (CSF) pharmacokinetics at the lower
end of the dosing range (at 100 and 300mg bid).
The treatment duration in part I was between 10
and 16 days, depending on the titration schedule.
Part II was a 30-patient, randomized, double-
blind, parallel-group, placebo-controlled design,
which evaluated two dose levels of Org 26576 for
28 days (10 subjects assigned to 100mg bid, 10
subjects assigned to 400mg bid, and 10 subjects
assigned to placebo), with objectives to evaluate
tolerability, pharmacokinetics, and pharmaco-
dynamics over an extended treatment period. The
doses in part II were selected on the basis of the
tolerability results from part I.
All selected patients were male or female, aged
18–65 years, and diagnosed withMDD according
to the fourth edition of the Diagnostic and Sta-
tisticalManual ofMental Disorders (DSM-IV-TR).
Current depressive episodes were mild to severe
without psychotic features, and no more than
2 years in duration, with a total score of at least 9
but not more than 20 on the Quick Inventory of
Depression Symptomatology – Clinician Rating
(QIDS-C).[31] Patients who had received antide-
pressant treatment with an adequate dose and
duration in the current episode were excluded.
Eligible patients were otherwise generally healthy
and medically stable; were taking no concurrent
psychotropic medications; and had no history of
bipolar disorder, psychosis, post-traumatic stress
disorder, obsessive-compulsive disorder, or eat-
ing disorder. Patients with a 6-month history of
substance dependence (not including nicotine),
current substance abuse, or a positive screen-
ing or admission urine drug/alcohol test were
excluded.
Subjects in both trials were admitted to the
unit 1–2 days before the first dosing and confined
for the full term of the dosing period. Diet and
physical activity were controlled, and subjects
were closely monitored for safety and tolerability.
Safety evaluations included regular AE assessments,
vital signs, 12-lead electrocardiograms (ECGs),
clinical laboratory assessments, and safety elec-
troencephalograms (EEGs) conducted in a rest-
ing state with eyes open and closed, with photic
stimulation, and with 3 minutes of hyperventila-
tion. In addition, the patient trial included frequent
suicidality assessment using the Beck Scale for
Suicidal Ideation (BSS).[32]
In study 1, the MTD was not specifically de-
fined a priori; however, safety and tolerability
were closely monitored by the study investigators
and the sponsor in a blinded fashion, and dosing
progression was largely dependent on absence of
medication discontinuations due to AEs. TheMTD
in study 2 was defined a priori as the dose one step
below the minimum intolerated dose (MID),
where the MID was the dose at which ‡50% of
subjects experienced multiple moderate AEs or a
single severe AE, or the dose at which a serious AE
occurred in one ormore subjects. Safety/tolerability
data were reviewed by the study investigators and
the sponsor on an interim and blinded basis be-
fore progression to the next dosing level/cohort.
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Pharmacokinetic Assessments
Pharmacokinetic assessments were performed
following a rich pharmacokinetic sampling scheme
in both studies. In study 1, pharmacokinetic sam-
ples were taken at pre-dose, at 5, 10, 15, 30, and
45 minutes, and at 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18,
24, 36, 48, and 72 hours post-dose upon single-
dose administration during part I and upon the
first (no 36-, 48-, or 72-hour samples) and final
dose (no 72-hour sample) in group 3 during part
II of this study. For group 4 during part II,
an identical sampling scheme was applied up to
12 hours post-dose on days 2 (100mg), 8 (225mg),
11 (325mg), and 14 (400mg), while additional phar-
macokinetic samples at 18 and 24 hours post-
dose were taken 18 and 24 hours after the final
dose. Pharmacokinetic assessments up to 4 hours
post-dose were performed under fasted conditions,
with the exception of group 3, where on days 5
and 6 the food effect (a high-fat breakfast) on the
pharmacokinetics of Org 26576 was specifically
investigated. In study 2, plasma pharmacokinetic
samples were taken at pre-dose, at 15, 30, and
45minutes, and at 1, 1.5, 2, 3, 4, 6, 8, and 12 hours
post-dose (but before the evening dose) within a
multiple-dosing scheme. To examine the extent to
which Org 26576 is able to cross the human blood-
brain barrier, continuous CSF was collected over
intervals of 30 minutes, starting 2 hours prior to
the morning dose through 12 hours following the
morning dose on day 1 and day 10 in cohort D
only (n = 6). In this study, patients were required
to eat a light breakfast 30 minutes before the
morning dose.
Study Medication
In Study 1, Org 26576 was provided as freeze-
dried cake and was reconstituted at the site phar-
macy in 10mL of sterile water and added to
a gelatin/mannitol solution in order to obtain a
final volume of 50mL. Placebo was composed of
50mL of the gelatin/mannitol solution. The re-
quired dose was administered as an oral solution.
In Study 2, Org 26576 and placebo were prepared
as indistinguishable capsules containing placebo,
50mg, or 100mg of Org 26576 for oral adminis-
tration. The change of medication from oral
solution to capsule was not expected to lead to
significant formulation-dependent differences in
the overall disposition of the drug. This assump-
tion was supported by the overall physicochemical
characteristics (Biopharmaceutica Classifica-
tion System [BCS] class I)[33] and the in vitro ab-
sorption, distribution, metabolism, and excretion
(ADME) profile of Org 26576 (Merck Sharp &
Dohme Corp., unpublished data).
Bioanalysis
Org 26576 and its internal standard were
isolated from ethylene diamine tetra-acetic acid
(EDTA) plasma by solid-phase extraction. Liquid
chromatography-mass spectrometry using turbo
electrospray ionization in multi-reaction mon-
itoring mode was performed in order to quantify
the concentration of Org 26576. The assay has
been validated over the range of 0.2–200 ng/mL.
Both trials utilized the same bioanalytic ap-
proach and followed the same standard operating
procedures. Laboratory assessments were con-




All endpoints for both studies were analyzed
using the all-subjects-treated population (partic-
ipants who took at least one dose of the study
medication). Descriptive statistics were calculated;
however, no statistical testing was performed.
Pharmacokinetics
In study 1, group 3, a one-way analysis of
variance (ANOVA) with a ‘Food’ factor and re-
peated measures for each subject on food was
applied to the parameters pertaining to treatment
with and without food (i.e. the maximum plasma
drug concentration [Cmax] during a dosage inter-
val at steady state [Cmax,ss], the time to reach Cmax
[tmax] following drug administration at steady
state [tmax,ss], and the area under the plasma con-
centration-time curve [AUC] from 0 to 12 hours
at steady state [AUC12,ss]), which were compared
by means of a one-way ANOVA with a ‘Food’
factor and repeated measures for each subject on
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food (i.e. a paired t-test). Food-independent
pharmacokinetics were to be concluded if the
food effect for all parameters analyzed was not
significant. An analogous analysis was applied to
explore the presence of a regimen effect (100mg
single dose on day 1, versus 100mg bid on day 9).
For this purpose, parameters pertaining to single
dosing (i.e. Cmax, tmax, the elimination half-life
[t½], and the AUC from time zero to infinity
[AUC¥]) and to steady state (i.e. Cmax,ss, tmax,ss,
t½,ss, and AUC¥,ss) were compared. Time-
independent pharmacokinetics were to be con-
cluded if the regimen effect for all parameters
analyzed was not significant. In group 4, the pa-
rameters (i.e. the dose-normalized [dn] Cmax,ss
[dn-Cmax,ss], tmax,ss, and dn-AUC12,ss) pertaining
to the escalating multiple dosing (100, 225, 325,
and 400mg) were compared by means of a two-
way ANOVA with fixed factors of ‘Dose’ and
‘Subject’. If there was no significant dose effect,
then the pharmacokinetics were to be considered
as linear within the dose range studied. In study 2,
the Org 26576 pharmacokinetic parameters in
part II (i.e. dn-Cmax, t½, dn-AUC, and tmax) were
compared by means of an ANOVA with fixed
factors of ‘Dose’ (low dose: Org 26576 100mg bid
group; high dose: Org 26576 400mg bid group),
‘Day’ (1, 4, 27), ‘Dose*Day’ interaction, and re-
peated measures for each subject (subject nested
within dose).
In both studies, loge-transformed values of the
parameters were used in the ANOVAs, except for
tmax, for which a Wilcoxon signed rank test was
performed. Effects were considered as significant
if the p-value was £0.05 (p: two-sided tail proba-
bility). Since these studies were not powered, all
p-values were to be interpreted in the perspective of
the explorative character of these trials. The plots,
parameters, and analysis pertaining to the pharmaco-
kinetic evaluations were generated using SAS release
9.1 under the Windows XP operating system.
Results
Baseline Characteristics
A total of 36 and 54 subjects were randomized
in the HV and patient studies, respectively (see
table I). All received at least one dose of study
medication and therefore qualified for the all-
subjects-treated population. All participants in
the HV study were male, as were the majority
(65%) in the patient study. The patient study
sample was more racially diverse and somewhat
older than the HV sample.Weight and body mass
index (BMI) were comparable between studies. In
the patient study, the majority of patients (76%)
were diagnosed with recurrent depression, and
the number of lifetime episodes was 4.4; the mean
QIDS-C total score at baseline was 15.1 (stan-




There were no serious or severe AEs in this
study. In study part I (single dose), no subjects
discontinued because of AEs. Doses of 100mg
and higher were associated with gastrointestinal
AEs (nausea, vomiting, once at 200 and 250mg)
and CNS AEs (dizziness, postural dizziness,
headache, and paraesthesia). The 100mg dose
was determined to be the single-dose MTD.
In part II of the study (multiple dose), Org
26576 100mg bid given for 7 days (group 3) was
well tolerated by all subjects. The AEs reported
most frequently in the active-treatment group
includedmild dizziness andmild nausea. In group 4,
where an up-titration schedule to 400mg bid was
applied, Org 26576 was tolerated up to doses of
225mg bid. However, at higher doses, three sub-
jects discontinued, two because of nausea and/or
vomiting (both at 325mg bid) and one because
of dizziness (at 400mg bid). The most common
treatment-emergent AEs associated with Org 26576
(occurring in ‡25% of subjects in the active-
treatment group of any study group, and with at
least 2· the incidence in the placebo group) were
nausea, dizziness, and somnolence, as well as feel-
ing drunk and postural dizziness. The MTD with
titration was determined to be 225mg bid.
There were no obvious treatment-related changes
observed either for individual subjects or in the
summary data for clinical laboratory values, vital
signs, or ECG measurements. During the dose-
132 Nations et al.
Adis ª 2012 Nations et al., publisher and licensee Springer International Publishing AG. Drugs R D 2012; 12 (3)
titration part of the study, five of six subjects
taking Org 26576, but no placebo subjects, had
EEG observations that were interpreted as non-
specific and indicative of drowsiness.
Study 2
No randomized patients experienced a serious
or severe AE. Two subjects discontinued the trial
because of AEs: one subject taking Org 26576 in
part I discontinued because of akathisia at the
highest dose (600mg bid), and one subject taking
placebo in part II discontinued because of tension
headache. Most subjects in the active-treatment
and placebo groups reported at least one AE
during the treatment period (Org 26576: 97%;
placebo: 89%). The treatment-emergent AEs re-
ported most frequently in the active-treatment
group (‡25% of subjects in either study part and
with at least 2· the incidence in the placebo group)
were insomnia, dizziness, nausea, muscle twitch-
ing, fatigue, and feeling drunk (described by
the investigator as a subjective feeling of ‘fuzzy
headedness’ without objective impairment). On
the basis of a post-study unblinded data review, it
was determined that in cohort C, two of four drug-
treated subjects experienced multiple moderate
AEs at the 600mg bid dose level. In addition, the
only active-treatment discontinuation – and, re-
gardless of titration schedule, the majority of
moderate AEs – occurred at the dose of 600mg
bid. Therefore, the MTD for this study was con-
sidered to be 450mg bid. The optimal starting dose
was determined to be 200mg bid on the basis of
the finding that the initial dose of 300mg bid was
associated with more treatment-related AEs than
the initial dose of 100 or 200mg bid.
There were no clinically significant drug-related
laboratory, vital sign, ECG, or EEG findings in
the study. Orthostatic tachycardia and orthosta-
tic hypotension occurred at higher rates in the
Table I. Demographic and baseline characteristics of randomized subjects
Characteristic Study 1:
Org 26576 in HVs
(n =36)
Study 2:
Org 26576 in MDD
patients (n= 54)
Treatment assignment (n [%])
Active 30 [83.3] 36 [66.7]
Placebo 6 [16.7]a 18 [33.3]
Sex (n [%])
Male 18 [100] 35 [64.8]
Female 0 19 [35.2]
Race (n [%])
Asian 1 [2.8] 3 [5.6]
Black 3 [8.3] 14 [25.9]
White 29 [80.6] 33 [61.1]
Other 1 [2.8] 4 [7.4]
Age (y; mean [range]) 27.6 [19–41] 35.4 [18–61]
Weight (kg; mean [range]) 77.1 [66.5–94.3] 76.9 [44.0–118.1]
Body mass index (kg/m2; mean [range]) 24.4 [22.0–28.0] 25.3 [19.0–31.9]
Baseline QIDS-C score (mean [SD]) NA 15.1 [2.26]
Course of depression
First episode (n [%]) NA 13 [24]
Recurrent (n [%]) NA 41 [76]
Total number of lifetime episodes (mean [range]) NA 4.4 [1–20]
a Accounts for those subjects who received placebo only (i.e. subjects who were part of the active/treatment crossover design of part I are not
counted in the placebo total).
HV = healthy volunteer; MDD =major depressive disorder; NA= not applicable; QIDS-C =Quick Inventory of Depression Symptomatology –
Clinician Rating; SD = standard deviation.
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drug-treated groups than in the placebo group,
though the findings were not considered clini-
cally significant by the investigator and were
not associated with any clinical signs. Nine sub-
jects taking active medication (in contrast with
zero placebo-treated subjects) had abnormal in-
treatment EEG observations, which were felt by
the investigator to be not clinically significant,
primarily associated with drowsiness, and not
indicative of pro-epileptic properties of the drug.
No notable differences were observed between
treatment groups in the baseline-to-endpoint
suicidality mean scores (as measured by the BSS).
Pharmacokinetics
As one aim of the current paper is to compare
the pharmacokinetic properties of Org 26576 in
two different populations, the pharmacokinetic
results reported here focus on the results obtained
from both studies for identical doses administered
in comparable multiple-dose regimens. Food and
regimen analysis results for HVs, as well as dose
and regimen results for MDD patients, are pre-
sented to further elucidate the overall pharma-
cokinetic profile of Org 26576.
Study 1: Food, Regimen, and Dose Effects
After oral administration, Org 26576was rapidly
absorbed as well as eliminated (see table II). Plasma
concentrations reached Cmax values about half an
hour post-dose and quickly decayed, with a t½ of
about 3 hours. These pharmacokinetic charac-
teristics were consistently observed upon single-
dose and multiple-dose administration of Org
26576 100mg as long as the volunteers were fasted.
Intake of a high-fat breakfast prior to dosing af-
fected the pharmacokinetic characteristics of Org
26576 by increasing tmax by about 40% and by
reducing Cmax by approximately 50%. AUC was
reduced by only 12% with food, which is within
the estimated variability of the parameter.[34]
This fed-state reduction in the absorption rate
translated into lower and smoothed plasma con-
centrations around the Cmax values observed in
fasted conditions. Regimen effect testing on the
loge-transformed pharmacokinetic parameters of
Org 26576 showed that no significant regimen
effects on Cmax, total exposure, or t½ were found.
Analogously, the Wilcoxon signed rank test in-
dicated no regimen effect on tmax.
The dose-normalized mean curves for all es-
calating doses in group 4 are displayed in figure 2,
and the descriptive statistics for key pharmaco-
kinetic parameters of the 100mg and 400mg bid
escalating doses in group 4 are shown in table III.
Cmax values increased subproportionally with
dose, while tmax and AUC values showed the op-
posite trend. When compared with the results in
group 3, the t½ was not clearly affected by the dose.
Table II. Pharmacokinetic parameters in group 3 healthy volunteers in study 1a
Parameter 100mg single dose 100mg bid
Day 1 fasted Day 9 fasted Days 5–6 fasted Days 5–6 fed
(n =6) (n =6) (n= 6) (n =6)
dn-Cmax (ng/mL/mg) 16.3 [22.8] 15.7 [34.8] 14.2 [20.9] 7.01 [19.4]
tmax (h; median [range]) 0.50 [0.25–0.75] 0.50 [0.50–1.03] 0.75 [0.50–1.00] 1.25 [0.25–4.00]
t½ (h) 2.94 [14.5] 2.8 [24.8] NA NA
dn-AUC¥ (ngh/mL/mg) 52.0 [40.2] 58.0 [47.7] NA NA
dn-AUC12 (ngh/mL/mg) NA NA 49.0 [38.4] 43.0 [37.1]
CL/F (L/h) 21.2 [28.8] 19.7 [32.2] 22.3 [27.6] 25.4 [28.3]
Vz/F (L) 87.2 [21.7] 75.6 [21.1] NA NA
a The values are expressed as arithmetic mean [CV%] unless specified otherwise.
AUC = area under the plasma concentration-time curve; AUC12=AUC from 0 to 12 hours; AUC¥ =AUC from time zero to infinity; bid = twice
daily; CL/F = apparent total drug clearance after oral administration; Cmax =maximum observed plasma drug concentration; CV = coefficient of
variation; dn = dose-normalized; NA =not applicable; t½ =elimination half-life; tmax= time to Cmax; Vz/F =apparent volume of distribution during
the terminal phase after oral administration.
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An overall trend for the dose effect was found
for dn-Cmax,ss (p = 0.09) and was significant for
dn-AUC12,ss (p = 0.03). The ANOVA on ranks of
tmax resulted in a significant dose effect, showing
larger tmax values for the highest doses (325 and
400mg) than for the lower doses (100 and
225mg).
Study 2: Dose and Day Effects
The mean dose-normalized plasma concen-
trations observed in part II of this study at days 1,
4, and 27 for the 100mg and 400mg bid treat-
ment groups are displayed in figure 3a and 3b,
respectively. The mean dn-Cmax and dn-AUC
values for days 4 and 27 in the 100mg bid treat-
ment group (see table III) were approximately
30% higher than for day 1 (data not shown). For
the 400mg bid treatment group, similar mean dn-
Cmax and dn-AUC values were found for all days.
The mean dose-normalized exposure values for
the 400mg bid group tended to be somewhat
higher than those for the 100mg bid group (see
table III). An explorative ANOVA on all subjects
in part II showed no statistically significant over-
all ‘Dose’, ‘Day’, or ‘Dose*Day’ effects on dn-
Cmax, tmax, dn-AUC, and t½. No major deviations
from the dose proportionality and time indepen-
dence of the kinetics of Org 26576 were observed
in this study in the titration schemes and dose
range tested. For cohort D of part I, the mean
Org 26576 exposure and concentration values
in plasma and CSF were similar, both on day 1
(100mg single dose) and on day 10 (300mg steady
state). The CSF tmax followed the plasma tmax by
approximately 15 minutes with single doses and
by approximately 1.5 hours with multiple doses.
Discussion and Conclusion
The studies presented herein describe bridg-
ing data for the AMPA PAM Org 26576. On
the basis of evidence suggesting that neuropsy-
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Fig. 2. Mean dose-normalized plasma concentrations of escalating
doses of Org 26576 in healthy volunteers.
Table III. Pharmacokinetic parameters in healthy volunteers in study 1 and in patients with major depressive disorder in study 2a
Parameter Study 1 in HVs Study 2 in MDD patients
100mg bid 400mg bid 100mg bid 400mg bid
Day 2 Day 14 Day 4 Day 27 Day 4 Day 27
(n =6) (n =3) (n= 10) (n= 10) (n =10) (n =9)
dn-Cmax (ng/mL/mg) 16.3 [38.3] 11.2 [25.8] 11.4 [46.3] 11.2 [34.1] 11.3 [30.8] 12.3 [57.4]
tmax (h; median [range]) 0.5 [0.25–0.50] 1.00 [0.75–1.50] 1.75 [0.75–2.13] 1.50 [0.75–2.00] 1.75 [0.75–4.0] 2.00 [0.75–4.00]
t½ (h) NA 2.40 [20.4] 2.1 [31.4] 2.3 [29.9] 2.49 [33.0] 2.47 [37.6]
dn-AUC12 (ngh/mL/mg) 34.5 [44.1] 38.9 [25.4] 49.1 [59.1] 48.4 [56.7] 56.6 [48.9] 61.7 [64.3]
CL/F (L/h) 33.6 [40.4] 27.0 [28.9] NA 27.2 [53.1] NA 35.5 [129]
Vz/F (L) NA 93.6 [34.1] NA 79.0 [34.1] NA 112 [105]
a The values are expressed as arithmetic mean [CV%] unless specified otherwise.
AUC12 =area under the plasma concentration-time curve from 0 to 12 hours; bid = twice daily; CL/F = apparent total drug clearance after oral
administration; Cmax =maximum observed plasma drug concentration; CV = coefficient of variation; dn = dose-normalized; HV = healthy
volunteer; MDD =major depressive disorder; NA = not applicable; t½ =elimination half-life; tmax = time to Cmax; Vz/F = apparent volume of
distribution during the terminal phase after oral administration.
Maximum Tolerated Dose Evaluation of Org 26576 135
Adis ª 2012 Nations et al., publisher and licensee Springer International Publishing AG. Drugs R D 2012; 12 (3)
doses than do HVs, the clinical development
plan for the Org 26576 program included both
phase I (HVs) and phase Ib (patients diagnosed
with MDD) multiple-rising-dose studies. The
primary objectives were to establish the MTD
and to fully characterize the safety, tolerability,
and pharmacokinetics in both populations.
Although the trials differed in several design ele-
ments, we believe that the data presented here are
both comparable and interpretable, given that they
are based on trial cohorts that included the same
multiple-rising-dose approach, starting dose, and
regimen; nearly identical titration steps; similar
housing conditions; and a similar safety assessment
strategy.
In the HV trial, Org 26576 was well tolerated
at doses of up to 225mg bid, while in depressed
patients, the MTD was 450mg bid – twice the
maximum dose established in HVs. The patient
trial also established that slightly faster titration
could be achieved without increasing the number
of dose-limiting AEs. The most common AEs as-
sociated with the study drug in both populations
included dizziness, nausea, and feeling drunk.
There were no clinically relevant safety issues
associated with Org 26576 at any dose in either
population.
In an attempt to learn whether better toler-
ability in patients could be explained by pharma-
cokinetic differences between populations, we
examined pharmacokinetic parameters for both
HVs and patients under highly comparable dos-
ing conditions. Multiple-dose administration of
Org 26576 at the same dose level in HVs and
MDD patients resulted in pharmacokinetic pro-
files that were similar overall, though not identi-
cal. In both populations, Org 26576 was rapidly
absorbed and disposed, with a t½ not longer
than 3 hours. Cmax and tmax values increased sub-
proportionally and underwent a time delay, sug-
gesting a dose-dependent, partially saturated
absorption process, although not statistically sig-
nificant. Further, no regimen effects were ob-
served, indicating linear kinetics over time. The
overall exposure of the drug, however, seemed to
be somewhat higher and tmax values seemed to be
greater in patients than in HVs. While the origin
of the exposure difference is unclear, food and
formulation effects cannot be entirely excluded as
underlying causes of the tmax difference.
Indeed, one of the principal limitations in this
population comparison is the difference between
studies under fed/fasted conditions. As is gen-
erally the case with early clinical drug develop-
ment, the phase I and Ib studies were conducted
in succession and were designed to build on ac-
cumulating animal and human data and other

















































Fig. 3. Mean dose-normalized plasma concentrations of Org 26576
on days 1, 4, and 27 for (a) the 100mg twice-daily dose and (b) the
400mg twice-daily dose in MDD patients.
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a food effect indicated that Cmax values were
higher in the fasted state than in the fed state,
suggesting that the Cmax ‘smoothing’ effect of
food intake prior to dosing could reduce the risk
and/or the frequency of peak-related AEs. Under
this assumption, the patient study protocol re-
quired all doses to be administered 30 minutes
after a meal. However, we do not believe that the
food effect on pharmacokinetics fully explains
the higher MTD in depressed patients. Cmax val-
ues were comparable between populations at the
higher doses, which were the points at which
dose-limiting AEs occurred, and the events that
drove MTD determination in both studies were
not often associated with tmax.
Another evolutionary program change was
the inclusion of females midway through the
patient trial following the finalization of animal
reprotoxicity studies. While the HV study in-
cluded only males, 36% of treated participants in
the patient study were female. Although this
change was necessary in order to examine safety
and tolerability in the broader target population,
it raises the question as to whether tolerability
differences between the trials can be attributed
to sex. However, post hoc evaluation showed
that exclusion of female subjects from the pa-
tient sample did not change the MTD determi-
nation at all.
An important difference between trials is how
theMTDwas defined. In the HV study, theMTD
was driven by discontinuations due to AEs. In the
patient study, the MTD was defined a priori as
the dose one step below theMID, where theMID
was the dose at which ‡50% of subjects experi-
enced multiple moderate AEs or a single severe
AE, or the dose at which a serious AE occurred in
one or more subjects. If we applied the HV ap-
proach to the patient study, the MTD result would
not change. In contrast, if we applied the patient
definition to the HV study, an MTD would not
be defined, because only one patient experienced
multiple moderate AEs. However, we note that
patients were much more likely than HVs to con-
tinue dosing despite moderate-intensity events.
In the HV trial, every subject who reported a
moderate AE ultimately discontinued treatment
because of the event. In contrast, only one par-
ticipant of nine who experienced moderate AEs
in the patient trial discontinued. Whether this is
due to better tolerability in general, greater mo-
tivation to stay in the treatment unit for lifestyle
reasons, the possibility of a treatment effect, dif-
ferences in the clinical approaches used by dif-
ferent sites and investigators, or some other factor,
is difficult to determine. Regardless, the MTD
determinations reflect the experience of the par-
ticipants and the clinical impressions of the
investigators, suggesting that the underlying def-
initions were appropriate for the populations
under study.
Although we certainly acknowledge the scien-
tific value of clearly defining theMTD in advance
of study implementation, we believe, on the basis
of this experience, that clinical judgment has an
equally important role. Given the very small
sample size included in most tolerability studies,
under strict a priori criteria small numbers of AEs
can drive theMTD determination.WhenAEs are
of questionable relationship to the study drug or
are reported by unreliable patients – or, con-
versely, when safety issues are seen that do not
easily fit the MTD criteria – rigid adherence to an
a priori definition could result in inappropriate
dose selection for phase II trials. For this reason,
the current phase Ib protocol included provisions
for independent unblinded data review if needed
to elucidate the tolerability profile, as well as
flexibility to allow clinical judgment in the final
determination of the MTD.
Whether better patient tolerability can be at-
tributed in this case to alteration of receptor ac-
tivity by previous antidepressant treatment is an
open question. Currently marketed antidepres-
sants are thought to have eventual downstream
effects on the glutamate system[35] and on AMPA
receptors themselves,[36] suggesting that a prior
treatment history could influence tolerability even
with this novel compound. However, we note
that in the current trial, patients presenting with
their first episode of depression (with no prior
antidepressant taken in that episode) and those
presenting with recurrent depression (and pre-
sumably a more robust treatment history) dem-
onstrated very comparable tolerability profiles.
Alternative explanations include the possibility
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that alteration of receptor activity by depression
itself drives better tolerability in patients. Indeed,
there is a growing body of evidence suggesting
that both glutamate activity[22-24] and AMPA
receptor expression[36] are altered in depressed
patients. However, the mechanism by which these
findings translate into decreased glutamate drug
sensitivity remains to be explored.
As a result of this detailed bridging work and
further information from animal and human
pharmacokinetic/pharmacodynamics modeling,
which predicted target levels of AMPA receptor
engagement at doses ranging from 100 to 400mg
bid,[37] the upper end of the dose range selected
for phase II efficacy trials was significantly higher
than the HVMTD. Final dose selection also took
into consideration the likelihood that patient
tolerability could differ in an outpatient setting,
where life demands may mediate the functional
impairment associated with drug-relatedAEs. Here
too, patient tolerability data helped to address
this question by providing critical information
regarding the time of onset, severity, and dura-
tion of AEs, and the tendency for specific events
to abate over time. The Org 26576 bridging data
therefore contributed to confident dose selection
for phase II trial planning and, as a result, served
the greater purpose of patient and program risk
minimization.
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